Unilabs SA Delivers 8th Consecutive Quarter Of Organic Sales And EBITDA Growth

GENEVA--(BUSINESS WIRE)--

“Our continued focus on generating profitable organic top-line growth combined with a strong focus on optimising our cost base has allowed us to deliver another quarter of solid EBITDA growth. Building on this momentum we see a healthy pipeline of commercial opportunities in the second half of the year.”

  • EBITDA: €33m, organic growth rate of 20.1% at constant exchange rates (CER)
  • Free cash flow: €12.4m
  • Cost savings1): €4.9m
  • Strong organic growth in the Laboratory segment: 5.1%
  • 2016 Guidance confirmed:
    • Organic sales growth of 4-5% (CER)
    • Organic EBITDA growth of 8-12% (CER)
    • Positive cash flow before M&A

1) Cost Leadership Initiative (CLS)

Unilabs Group reports a strong second quarter performance for 2016. Commenting on the results, Jos Lamers, Chief Executive Officer stated, “Our continued focus on generating profitable organic top-line growth combined with a strong focus on optimising our cost base has allowed us to deliver another quarter of solid EBITDA growth. Building on this momentum we see a healthy pipeline of commercial opportunities in the second half of the year.”

Medical diagnostics continue to play an increasingly important role in a steadily growing healthcare market. With a shifting focus from treatment to prediction and prevention, medical diagnostics contributes to reducing the cost pressure on healthcare systems and provides a favourable market outlook for Unilabs.


For full article, please click here.
MORE ON THIS TOPIC